title: European Medicines Agency must take account of cardiovascular harm associated with degludec insulin.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Schmidt
authors.forename: Clifford J
authors.initials: CJ
authors.lastname: Rosen
authors.forename: John S
authors.initials: JS
authors.lastname: Yudkin
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D005062:European Union; D005260:Female; D006077:Government Agencies; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D049528:Insulin, Long-Acting / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011358:Product Surveillance, Postmarketing; D011634:Public Health; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; C571886:insulin degludec